Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: A study by the EORTC-PAMM-NDDG

Clinical Pharmacokinetics

Volumn 46, Issue 12, 2007, Pages 1051-1068

  Joerger, Markus ^a,b,w   Huitema, Alwin D R ^a   Richel, Dick J ^c   Dittrich, Christian ^d   Pavlidis, Nikolas ^e   Briasoulis, Evangelos ^e   Vermorken, Jan B ^f   Strocchi, Elena ^g   Martoni, Andrea ^h   Sorio, Roberto ⁱ   Sleeboom, Henk P ^j   Izquierdo, Miguel A ^k   Jodrell, Duncan I ^l   Féty, Régine ^m   De Bruijn, Ernst ⁿ   Hempel, Georg ^o   Karlsson, Mats ^p   Tranchand, Brigitte ^q,r,s   Schrijvers, Ad H G J ^t   Twelves, Chris ^u   Beijnen, Jos H ^a,b,v   Schellens, Jan H M ^b,v   more..

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c MEDISCH SPECTRUM TWENTE   (Netherlands)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^f ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j LEYENBURG HOSPITAL   (Netherlands)

^k CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^l UNIVERSITY OF EDINBURGH   (United Kingdom)

^m CENTRE RENÉ GAUDUCHEAU   (France)

ⁿ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^o UNIVERSITY OF MÜNSTER   (Germany)

^p UPPSALA UNIVERSITY   (Sweden)

^q CENTRE LÉON BÉRARD   (France)

^r UNIVERSITÉ DE LYON   (France)

^s UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

^t EORTC DATA CENTER   (Belgium)

^u UNIVERSITY OF LEEDS   (United Kingdom)

^v UTRECHT UNIVERSITY   (Netherlands)

^w NETHERLANDS CANCER INSTITUTE   (Netherlands)

more..

Author keywords

Breast cancer; Cyclophosphamide, pharmacokinetics; Doxorubicin, pharmacokinetics; Pharmacokinetic modelling; Population pharmacokinetics

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CREATININE; CYCLOPHOSPHAMIDE; DOXORUBICIN; DOXORUBICINOL; GRANISETRON; METOCLOPRAMIDE; ONDANSETRON;

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BREAST CANCER; CANCER PATIENT; CONFIDENCE INTERVAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG RESPONSE; EARLY CANCER; EPILEPSY; ERYSIPELAS; FEBRILE NEUTROPENIA; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALAISE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; NONLINEAR SYSTEM; PHARMACODYNAMICS; PHARMACOKINETICS; POPULATION RESEARCH; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA;

EID: 36249031853     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200746120-00005     Document Type: Article

References (37)

1. Beslija S, Bonneterre J, Burstein H, et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007; 18: 215-25
2. Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003; 21 (6): 968-75
3. Biganzoli L, Cufer T, Bruning P, et al. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: the European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial. J Clin Oncol 2002; 20 (14): 3114-21
4. Jones SE, Clark G, Koleszar S, et al. Adjuvant chemotherapy with doxorubicin and cyclophosphamide in women with rapidly proliferating node-negative breast cancer. Clin Breast Cancer 2002; 3 (2): 147-52
5. Fumoleau P, Chauvin F, Namer M, et al. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes. J Clin Oncol 2001; 19 (3): 612-20
6. Evans TR, Yellowlees A, Foster E, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: an Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005; 23 (13): 2988-95
7. Smith RE, Anderson SJ, Brown A, et al. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58. Clin Breast Cancer 2002; 3 (5): 333-40
8. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 (16): 1673-84
9. Slamon D, Eiermann W, Robert N, et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC-T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC-T) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study [abstract]. Breast Cancer Res Treat 2005; 94 Suppl. 1: 5
10. Twelves CJ, Dobbs NA, Gillies HC, et al. Doxorubicin pharmacokinetics: the effect of abnormal liver biochemistry tests. Cancer Chemother Pharmacol 1998; 42 (3): 229-34
11. Freyer G, Tranchand B, Ligneau B, et al. Population pharmacokinetics of doxorubicin, etoposide and ifosfamide in small cell lung cancer patients: results of a multicentre study. Br J Clin Pharmacol 2000; 50 (4): 315-24
12. Rudek MA, Sparreboom A, Garrett-Mayer ES, et al. Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy. Eur J Cancer 2004; 40 (8): 1170-8
13. Robert J, Armand JP, Huet S, et al. Pharmacokinetics and metabolism of 4′-iodo-4′-deoxy-doxorubicin in humans. J Clin Oncol 1992; 10 (7): 1183-90
14. de Jonge ME, Huitema AD, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005; 44 (11): 1135-64
15. de Jonge ME, Huitema AD, Beijnen JH, et al. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94 (9): 1226-30
16. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 1992; 10 (6): 995-1000
17. Friberg LE, Henningsson A, Maas H, et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20 (24): 4713-21
18. Ratain MJ, Robert J, van der Vijgh WJ. Limited sampling models for doxorubicin pharmacokinetics. J Clin Oncol 1991 May; 9 (5): 871-6
19. van Asperen J, van Tellingen O, Beijnen JH. Determination of doxorubicin and metabolites in murine specimens by high performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 712 (1-2): 129-43
20. Egorin MJ, Forrest A, Belani CP, et al. A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 1989 Jun 1; 49 (11): 3129-33
21. Huitema ADR, Tibben MM, Kerbusch T. Simulataneous determination of N,N′,N″-triethylenethiphosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl 1998; 716: 177-86
22. Beal SL, Sheiner LB. NONMEM user's guide. San Francisco (CA): University of California NONMEM Project Group, 1998
23. Jonsson EN, Karlsson MO. Xpose - an S-Plus based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58 (1): 51-64
24. Joerger M, Huitema AD, Meenhorst PL, et al. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma. Cancer Chemother Pharmacol 2005; 55 (5): 488-96
25. Friberg LE, Freijs A, Sandstrom M, et al. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats. J Pharmacol Exp Ther 2000; 295 (2): 734-40
26. Sandstrom M, Lindman H, Nygren P, et al. Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 2005; 23 (3): 413-21
27. Palle J, Frost BM, Peterson C, et al. Doxorubicin pharmacokinetics is correlated to the effect of induction therapy in children with acute myeloid leukemia. Anticancer Drugs 2006; 17 (4): 385-92
28. McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005; 78 (3): 298-308
29. Petros WP, Broadwater G, Berry D, et al. Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancer. Clin Cancer Res 2002; 8 (3): 698-705
30. Belfayol-Pisante L, Guillevin L, Tod M, et al. Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP/aldophosphamide in systemic vasculitis. Fundam Clin Pharmacol 2000; 14 (4): 415-21
31. Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos 1997; 25 (5): 544-51
32. Sladek NE, Doeden D, Powers JF, et al. Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 1984; 68 (10): 1247-54
33. de Jonge ME, Huitema AD, van Dam SM, et al. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with thiotepa and carboplatin. Ther Drug Monit 2005; 27 (6): 756-65
34. de Jonge ME, Huitema AD, van Dam SM, et al. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother Pharmacol 2005; 55 (5): 507-10
35. Dobbs NA, Twelves CJ, Gillies H, et al. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol 1995; 36 (6): 473-6
36. Mross K, Mayer U, Hamm K, et al. Pharmacokinetics and metabolism of iodo-doxorubicin and doxorubicin in humans. Eur J Clin Pharmacol 1990; 39 (5): 507-13
37. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol 2003; 51 (5): 395-402